The FDA approved a first medicine for a rare kidney-scarring disease
Sparsentan cut proteinuria nearly in half in the DUPLEX trial's FSGS patients. Its effect on the eGFR measure that tracks actual kidney function decline was smaller, and comes with a liver-monitoring requirement.
The FDA approved sparsentan (Filspari) on April 13 to reduce proteinuria in patients with focal segmental glomerulosclerosis, or FSGS, who do not have nephrotic syndrome — the first medicine approved in the United States specifically for the disease [s1]. The company estimates more than 30,000 people in the US have the condition being addressed by this specific indication [s1].
FSGS is a pattern of kidney scarring, not a single disease with one cause, and it has historically been managed with off-label use of blood pressure medications and steroids rather than any drug developed and approved for it directly. Sparsentan's approval changes that — but the trial data behind it tells a more layered story than "first approved treatment" implies on its own.
What the trial measured, and what it found
The approval rests on the Phase 3 DUPLEX trial, a global, randomized, double-blind study comparing sparsentan against irbesartan — an existing blood-pressure drug used off-label in FSGS — in 371 patients ages 8 to 75 with biopsy-proven or genetically confirmed FSGS [s1]. In the subgroup of patients without nephrotic syndrome (the population covered by this specific approval), sparsentan produced a 48% reduction in proteinuria from baseline to week 108, compared with a 27% reduction on irbesartan — a statistically significant difference (p=0.0075) [s1].
Proteinuria — protein leaking into urine — is a marker of kidney damage, not kidney function itself. The trial's other reported measure, estimated glomerular filtration rate (eGFR), tracks actual filtering capacity, which is what ultimately determines whether a patient's kidneys are failing. On that measure, the treatment difference was smaller: eGFR declined by a mean of 11.3 mL/min/1.73m² on sparsentan by week 108, compared with a decline of 12.4 mL/min/1.73m² on irbesartan — a difference of 1.1 mL/min/1.73m² [s1].
That gap is real but modest. Both groups' kidney function declined over the nearly two-year trial; sparsentan slowed, rather than reversed or halted, that decline relative to an active comparator that itself is already used off-label as standard supportive care. The approval is grounded primarily in the larger, statistically robust proteinuria effect, with the eGFR data offered as supportive rather than as the headline result.
The safety tradeoff
Sparsentan's five most common adverse reactions, each occurring in at least 5% of patients, were peripheral edema, hypotension (including on standing), high potassium, dizziness, and anemia [s1]. A more specific concern is liver enzyme elevation: up to 3.5% of sparsentan-treated patients had aminotransferase levels rise to three times the upper limit of normal or higher [s1]. Because of that signal, the drug carries a Risk Evaluation and Mitigation Strategy (REMS) requiring enrollment and regular liver function monitoring for patients taking it [s1].
That combination — a real but modest kidney-function benefit alongside a monitored liver-safety risk — is a genuine tradeoff, not a formality. It is the kind of balance patients and clinicians will need to weigh individually, particularly for a chronic condition where any treatment is likely to be taken for years.
Why "first approved" is still significant
FSGS not associated with a specific identified genetic or secondary cause has had no FDA-approved treatment until now; clinicians have relied on repurposed drugs — corticosteroids, ACE inhibitors, angiotensin receptor blockers — without trial data generated in FSGS patients specifically. An approval built on a dedicated, randomized, head-to-head trial against the standard off-label comparator gives clinicians the first evidence base designed around this population rather than extrapolated from other kidney diseases.
Sparsentan's manufacturer, Travere, describes an addressable population of more than 30,000 patients with FSGS without nephrotic syndrome in the US, within a broader estimated 100,000-person population across sparsentan's combined approved indications, which also includes IgA nephropathy [s1].
What to watch
Long-term outcomes — whether the eGFR difference observed through week 108 translates into meaningfully delayed kidney failure or dialysis over years rather than the two-year trial window — remain to be established through continued follow-up and post-marketing data. The REMS liver monitoring requirement will also shape how the drug is used in practice, since it adds an ongoing monitoring burden that off-label comparators do not carry.
This article is informational and is not medical advice.
Sources
- [s1] Travere Therapeutics (Investor Relations), "Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan) in FSGS," 13 April 2026. https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Announces-Full-FDA-Approval-of-FILSPARI-sparsentan-the-First-and-Only-Approved-Medicine-for-FSGS/default.aspx
Sources
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan) in FSGS — Travere Therapeutics (Investor Relations) , April 13, 2026
A second apoC-III drug clears FDA for an ultra-rare fat disorder, 11 months on
Redemplo (plozasiran) is dosed once every three months. The approval carries required studies on liver injury, dysglycaemia and carcinogenicity, and skipped an advisory committee.
FDA approves the first treatment for TK2 deficiency, on evidence from 78 matched pairs
Kygevvi is a pair of oral nucleosides for an ultra-rare mitochondrial myopathy. There was no randomised trial — survival in treated patients was compared with untreated patients drawn from the literature.
FDA approves the first drug aimed at the cause of narcolepsy type 1, not just its symptoms
Orzeyful replaces signaling from the brain chemical narcolepsy patients lack, rather than stimulating wakefulness around the gap. Two-thirds of patients on the higher dose had trouble sleeping.
FDA clears first gene therapy for a rare disorder managed with round-the-clock cornstarch
GENGLYCOS treats the cause of glycogen storage disease type Ia, not just the symptoms cornstarch regimens manage — but it carries a long list of serious risks and an accelerated-approval asterisk.